Article: Sinovac Biotech Ltd. Has Received a Further US $1.2 Million in Government Research Funding for SARS Vaccine.

BEIJING -- Sinovac Biotech Ltd. ("Sinovac") (OTCBB:SNVBF) announced that Sinovac has received a further US $1.2 million in research funding from the Chinese state government for its inactivated SARS vaccine development program. To date, this brings the total amount of government support for Sinovac's SARS vaccine program to US $2.2 million. It is expected that funding of Sinovac's SARS vaccine development program will continue to be supported by the Chinese government.

Management of Sinovac believes that because of its low-cost advantage in China, a significantly larger budget would be required in the United States or Europe to conduct similar research and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!